National Comprehensive Cancer Network

Impact: The National Comprehensive Cancer Network hosted its 2026 Annual Conference, bringing together oncology professionals to discuss advancements in cancer care, research, and guidelines.

Impact: The National Comprehensive Cancer Network announced the selection of Nancy L. Lewis as its new Chief Scientific Officer, which is expected to advance its programs in clinical trials and cancer care.

Impact: The National Comprehensive Cancer Network>>> (NCCN) has updated and expanded the availability of its Distress Thermometer and Problem List, a key tool for cancer care, making it accessible in over 70 languages. This enhances its global reach and impact on patient care.

Impact: The National Comprehensive Cancer Network launched a new free email service to provide weekly updates on its NCCN Clinical Practice Guidelines in Oncology, aiming to improve access to current cancer treatment recommendations.

Impact: The NCCN's Category 1 recommendation for Signatera MRD-guided adjuvant atezolizumab in bladder cancer guidelines adds clinical credibility and may influence adoption.

Impact: The National Comprehensive Cancer Network's risk groups are used as a benchmark against which the Prolaris Biopsy Test's prognostic information is shown to add significant value.

Impact: NCCN Guidelines include Zegfrovy as a Category 2A subsequent therapy option.